Durability of Immunity Is Low Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1, BA.2, and BA.3 Variants After Second and Third Vaccinations in Children and Young Adults With Inflammatory Bowel Disease Receiving Biologics.

"Conflicts of Interest The authors disclose no conflicts."

"Funding The antibody characterization work was supported by the US 10.13039/100009210Food and Drug Administration Perinatal Health Center of Excellence (grant no. GCBER005) to Surender Khurana. The clinical study was funded by the 10.13039/100000071National Institute of Child Health and Human Development at the 10.13039/100000002National Institutes of Health (grant no. 5R61HD105613) to Juan C. Salazar. The funders had no role in study design, data collection and analysis, interpretation, writing, decision to publish, or preparation of the manuscript. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services and the mention of trade names, commercial products, or organizations does not imply endorsement by the US Government."